bioAffinity Technologies Secures Patent for AI-Powered Lung Cancer Detection Test

bioAffinity stock soars after receiving patent allowance for AI lung cancer test By Investing.com

Investing.com -- bioAffinity Technologies Inc (NASDAQ:BIAF) stock surged 14% on Thursday after the biotechnology company announced it received a notification of allowance from the United States Patent and Trademark Office for a new patent covering its AI-built algorithm and flow cytometry platform for lung cancer detection. The patent, titled "Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning," covers a system and method for predicting lung cancer likelihood by analyzing patient sputum samples. The company's CyPath® Lung test uses advanced flow cytometry to detect cancer-related changes in the lung. "Artificial intelligence was integral to the development of our CyPath® Lung test and has resulted in the detection of lung cancer at its earliest Stage 1A, a potentially curative stage," said Maria Zannes, President and CEO of bioAffinity Technologies. The company noted that a quarter of a million Americans are expected to receive a lung cancer diagnosis in 2025, representing the leading cause of cancer death. The CyPath® Lung test is designed to help physicians determine next steps for patients with pulmonary nodules requiring follow-up. This newly allowed U.S. patent adds to bioAffinity's expanding global patent estate, which now includes 18 awarded and 33 pending patents across multiple countries including the U.S., Canada, China, France, Germany, Hong Kong, Italy, Japan, Mexico, Spain, Sweden, and the United Kingdom. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

BioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

bioAffinity Technologies, Inc. announced it has received a notification of allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering the AI-built algorithm and flow cytometry platform that analyzes cell populations in sputum leading to detection of lung cancer. The patent, titled "Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning," covers a system and method for predicting the likelihood of lung cancer by analyzing patient sputum samples. CyPath®? Lung's advanced flow cytometry process detects changes in the lung linked to cancer, including populations of immune cells, apoptotic cells and cancer and cancer-related cells labeled by the Company's proprietary TCPP porphyrin. CyPath®? lung's AI-driven analysis combines these variables with patient age to predict cancer in the lung. CyPath®? Lung can be utilized by physicians to determine next steps for patients with pulmonary nodules requiring follow-up. The noninvasive test is designed to perform with high sensitivity and specificity and seeks to deliver valuable diagnostic insight while alleviating patient anxiety, preventing unnecessary invasive procedures and reducing costs to the healthcare system. This newly allowed U.S. patent complements bioAffinity's expanding global patent estate, which now includes 18 awarded and 33 pending patents. bioAffinity Technologies holds patents in the U.S., Canada, China, France, Germany, Hong Kong, Italy, Japan, Mexico, Spain, Sweden, and the United Kingdom. CyPath®? Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath®? Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath®? Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival.